Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy, in Patients with RRMM: CRB-401 Study Updates

Conference Correspondent  - ASH Highlights

CRB-401 is a phase 1 study evaluating the efficacy and tolerability of idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed and/or refractory multiple myeloma (RRMM). The primary end point was safety; secondary end points included tumor response based on the International Myeloma Working Group criteria; and exploratory end points included progression-free survival (PFS), overall survival (OS), and minimal residual disease (MRD). Although favorable phase 1 and 2 data have been published, updated efficacy and safety data are now available for 62 patients who continued therapy in this ongoing study.

The expansion phase of this 2-part dose-escalation and dose-expansion study enrolled patients who had received ≥3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and who were refractory to their last line of therapy. First, patients completed lymphodepletion with fludarabine and cyclophosphamide for 3 days and then rested for 2 days. Subsequently, ide-cel was administered at target doses of 50, 150, 450, or 800 × 106 CAR+ T-cells in the dose-escalation phase and 150 to 450 × 106 CAR+ T-cells in the dose-expansion phase.

The current updated analysis through January 14, 2020, includes 21 and 41 patients who received ide-cel in the dose-escalation phase and dose-expansion phase, respectively. A total of 45% of patients (28/62) had received >6 prior regimens, and 90% and 77% had been previously exposed to, or were refractory to, daratumumab, respectively. The median age in the study was 61 years, and high tumor burden, defined as ≥50% bone marrow CD138+ plasma cells, was observed in 44% of patients. Six deaths occurred within 6 months, all attributed to myeloma.

Regarding adverse events (AEs), 92% of patients experienced neutropenia, 76% developed cytokine release syndrome (CRS), and 76% and 74% experienced anemia and thrombocytopenia, respectively. Among grade 3/4 AEs, neutropenia, leukopenia, anemia, and thrombocytopenia were the most common, observed in 89%, 61%, 57%, and 57% of patients, respectively. Most CRS was grade 1/2, with only 4 (7%) patients experiencing grade 3 CRS, the incidence of which generally increased with higher doses. Twenty-two (36%) patients experienced neurologic toxicity, the majority of which was grade 1 (1 grade 4 event was recorded).

The overall response rate in this updated analysis was 76%, with 39% of patients achieving complete response or better (≥CR), and 65% of patients achieving a very good partial response or better. Median duration of response was 10.3 months. All patients with ≥CR, with qualified assessment, were MRD negative. Median PFS was 8.8 months and median OS was 34.2 months for all 62 patients. Clinical benefit appeared to be dose-dependent, as higher response rates and better survival outcomes were observed for patients who received ≥150 × 106 CAR+ T-cells.

Results from this updated analysis of the CRB-401 study are consistent with previous reports showing deep and durable responses for heavily pretreated patients with RRMM who received ide-cel. A favorable clinical benefit–risk profile at target doses ≥150 × 106 CAR+ T-cells was observed.


Reference

Abstract 131. ASH 2020. December 5, 2020. Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study.

Related Items
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.